v-domain ig suppressor of t-cell activation (vista)

NSC622608 is a small-molecule ligand for V-domain Ig suppressor of T-cell activation (VISTA) which is an immune checkpoint that affects the ability of T-cells to attack tumors.

VISTA-IN-2 (Compound 1) is a V-domain Ig suppressor of T-cell activation (VISTA) inhibitor that promotes the degradation of VISTA in cells via autophagy, reverses VISTA-related immunosuppression, and enhances the antitumor responses of immune cells. This compound also stimulates antitumor immunity and suppresses tumor growth in a CT26 mouse model [1].

Onvatilimab (JNJ-61610588) is a human IgG1 κ-anti-Vista (T-cell-activated V-domain Ig inhibitor) monoclonal antibody with antitumor activity, potentially used for treating advanced head and neck cancers.

M351-110 is an agonist of the V-domain Ig suppressor of T cell activation (VISTA) designed for oncological studies [1].

MG-V-53 is an efficacious small-molecule inhibitor of the V-domain Ig suppressor of T cell activation (VISTA), exhibiting an IC50 of 121 nM and possessing antitumor activity.